已收盘 08-01 16:00:00 美东时间
-0.230
-12.50%
今日重点评级关注:丰业银行:维持Arcellx"跑赢大市"评级,目标价从93美元升至133美元;RBC Capital:维持Precision Drilling"跑赢大市"评级,目标价从89美元升至100美元
08-01 10:17
In the latest quarter, 4 analysts provided ratings for Pulmonx (NASDAQ:LUNG), s...
08-01 03:00
Piper Sandler analyst Jason Bednar downgrades Pulmonx (NASDAQ:LUNG) from Overweight to Neutral and lowers the price target from $9 to $2.5.
07-31 20:10
Gainers OSR Holdings (NASDAQ:OSRH) stock rose 21.4% to $1.05 during Wednesday'...
07-31 05:06
Pulmonx shares are trading lower after the company reported Q2 financial result...
07-31 05:04
Pulmonx (NASDAQ:LUNG) lowers FY2025 sales outlook from $96.000 million-$98.000 million to $90.000 million-$92.000 million vs $96.951 million estimate.
07-31 04:13
Pulmonx (NASDAQ:LUNG) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.40) by 5 percent. This is a 2.56 percent increase over losses of $(0.39) per share from the same
07-31 04:08
新药研发,一场投入动辄十亿美元、耗时十年的持久战。在MNC巨头环伺的战场中,没有顶级的研发引擎,国内药企连入局的资格都没有。 当双抗、ADC成为创新药内卷的赛道...
07-30 16:28
Pulmonx Corporation (Nasdaq: LUNG), a global leader in minimally invasive lung disease treatments, announced it will present at the Canaccord Genuity 45th Annual Growth Conference in Boston on August 12, 2025. The presentation will be available live and archived on the company’s investor website. Pulmonx develops innovative devices like the Zephyr Endobronchial Valve and Chartis Pulmonary Assessment System to treat severe emphysema/COPD. The Zeph...
07-29 20:05
Pulmonx Corporation announced on July 16, 2025, that it will release its second-quarter 2025 financial results after market close on July 30, 2025. A conference call to discuss the results will follow at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast will be available on the Pulmonx investor website. Pulmonx is a global leader in minimally invasive lung disease treatments, offering products like the Zephyr® Endobronchial Valve for emphy...
07-16 20:05